Business Wire Industry News

Wednesday, March 22, 2023

Internship Program Empowers Canada’s Next Generation of Bio-Economy Workers

OTTAWA, Ontario--(BUSINESS WIRE)-- #HR--BioTalent Canada celebrates the National Day of Work-Integrated Learning (WIL), today, by releasing the impacts of their student work experiences – through the Student Work Placement Program (SWPP). The Program continues to empower the next generation of bio-economy workers. Since 2017, BioTalent Canada’s project under the SWPP has successfully placed more than 11,000 students with work placements at leading biotechnology organizations across Canada, including

Wednesday, March 22, 2023

BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

OTTAWA, Ontario--(BUSINESS WIRE)--BIOTECanada welcomes the government’s dedicated investment of $1.5 B over 3 years to advance effective access to medicines, improve evidence and decisions for the care of patients with rare diseases. The integrated approach, bringing federal, provincial and territorial governments together with national clinical practice expertise networks including clinicians, researchers and industry will be key to creating a national access program to address the long-standi

Wednesday, March 22, 2023

AmbioPharm to Host a Sustainable Peptide Manufacturing Workshop at Biologics 2023

NORTH AUGUSTA, S.C.--(BUSINESS WIRE)-- #cGMP--AmbioPharm, a worldwide leader in peptide API CDMO services, to host a workshop on sustainable peptide manufacturing at Biologics 2023 taking place in London, UK on March 29, 2023. The workshop, entitled “Holistic Approaches to Sustainable Peptide Manufacturing,” will comprise of industry presentations and a roundtable discussion with AmbioPharm and industry leaders from Novo Nordisk and Astra Zeneca. The peptide manufacturing industry, like others, is push

Wednesday, March 22, 2023

FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that its Australian entity, FSD Pharma Australia Pty Ltd. received the certificate of approval from The Alfred Ethics Committee in Australia to proceed with a Phase 1 clinica

Wednesday, March 22, 2023

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

VAUGHAN, Ontario & HEIDELBERG, Germany--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today announced that American Journal of Ophthalmology has published results from MOJAVE, the second pivotal Phase 3 trial for NOV03 (perfluorohexyloctane). NOV03 is being investigated

Tuesday, March 21, 2023

BELLUS Health Reports Year 2022 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the year ended December 31, 2022. “In 2022, we laid the groundwork to advance camlipixant, our P2X3 receptor

Tuesday, March 21, 2023

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic. Enveric Therapeutics will

Tuesday, March 21, 2023

NeuPath Announces Preliminary Financial Results for Fiscal 2022

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, is pleased to provide an update with selected preliminary unaudited results for the fourth quarter of 2022 and the full year ended December 31, 2022. The Company plans to release its audited fiscal 2022 financial results before markets open on Thursday, March 30, 2023. Preliminary unaudited financial results for t

Tuesday, March 21, 2023

KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After Opening

GENEVA--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced that late in 2022, it successfully released its inaugural First In Human (FIH) manufacturing batch in compliance with current Good Manufacturing Practice (cGMP) standards in its recently expanded Geneva mammalian cell manufacturing facility. The swift execution of this important milestone demonstrates the capabilities in cell line development (CLD) and biologics manufacturing of KBI and Selexis, all

Tuesday, March 21, 2023

Manitoba Becomes a Provincial Trailblazer in Providing Simplified Access to Advanced Glucose Monitors

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced that its Dexcom G6 CGM System will be available to people of all ages with type 1 and type 2 diabetes in Manitoba who meet eligibility criteria. Expanding coverage for rtCGM to include all eligible patients with type 1 or type 2 diabetes establishes Manitoba as the leader among Canadian provinces. As of this announcement,

Monday, March 20, 2023

Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has entered into an amended and restated secured loan agreement (the “Amended Loan Agreement”) with Long Zone Holdings Inc. (“LZH”), amending and restating the original secured loan agreement by and between Appili and LZH dated March 25, 2022 (the “Original Lo

Friday, March 17, 2023

Rhythmlink Announces Investment Partnership With Graham Partners

COLUMBIA, S.C.--(BUSINESS WIRE)--Rhythmlink International, LLC is pleased to announce an exciting new investment partnership with Graham Partners, a Pennsylvania-based private equity firm that specializes in industrial technology and advanced manufacturing businesses. As a market leading designer and manufacturer of disposable neurodiagnostic devices and consumables, Rhythmlink has experienced significant growth since its founding in 2002, and this investment from Graham will ensure that growth

Thursday, March 16, 2023

Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2023

OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2023. First Quarter January 31, 2023, Financial Results The Company’s unaudited Financial Stat

Thursday, March 16, 2023

Alpha Cognition Closes Private Placement

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, is pleased to announce that it has closed a second tranche of its previously announced private placement (the “Offering”) of units (the “Units”). Pursuant to the second tranche, the Company issued 6,952,427 Units of the Company at a price of $0.255 per Unit, for

Thursday, March 16, 2023

Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $KONEF #psychedelics--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at the upcoming Benzinga Psychedelic Capital Conference taking place on April 13th, 20

Thursday, March 16, 2023

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended January 31, 2023. “We are thrilled to announce that this quarter has been a foundational one for our company. Our project revenue has experienced a significant increase, thanks to our recognized best-in-class platform of function-first

Thursday, March 16, 2023

IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced alongside the release of its fourth quarter and annual results that it has engaged Stonegate Healthcare Partners, L.L.C (“Stonegate”) to explore strategic alternatives following a review of its business. “The early